Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cediranib maleate works in treating patients with
recurrent or metastatic kidney cancer that cannot be removed by surgery. Cediranib maleate
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.